780 / 1266
BRAFV600 Mutations –pHGG Target?
•
Good Target?
•
PROs
–
Established oncogene with known mechanism
–
Established clinical drugs & validated biomarkers
–
Proof of mechanism and concept proven in melanoma
•
CONs
–
Low prevalence in pHGG (6-8%)
–
Target can be heterogenous in tumours
–
Resistance can be inherent or acquired